The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
Abstract
Investigations over the past 20 years have demonstrated that antibacterials can vary markedly in the time course of antimicrobial activity. These differences in pharmacodynamic activity have implications for optimal dosage regimens. The results of more recent studies suggest that the magnitude of the pharmacokinetic/pharmacodynamic parameters required for efficacy are relatively similar in animal infection models and in human infections. However, there is still much to learn. Additional studies are needed to further correlate pharmacokinetic/pharmacodynamic parameters for many antibacterials with therapeutic efficacy in a variety of animal infection models and in human infections. The potential value of using pharmacokinetic/pharmacodynamic parameters as guides for establishing optimal dosing regimens for new and old drugs and for new emerging pathogens and resistant organisms, for setting susceptibility breakpoints, and for reducing the cost of drug development should make the continuing search for the therapeutic rationale of antibacterial dosing of mice and men worthwhile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139 · cited 1×
“However, the opposite was observed in the major clinical trials correlating pharmacokinetic/pharmacodynamic parameters with the therapeutic efficacy of aminoglycosides [56].”
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101 · cited 2×
“[52] found that a 24-hour AUC/MIC value of > 125 was associated with satisfactory outcome for seriously ill patients treated with intravenous ciprofloxacin.”
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720 · cited 3×
“need to exceed the MIC for 100% of the dosing interval to exert a significant antibacterial effect [25-27, 36].”
Self-citationCraig, W. A. (1995) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(95)00053-d · Cited by 618 · cited 5×
“Several investigators have used multiple dosage regimens in animal infection models to correlate specific pharmacokinetic/pharmacodynamic parameters with the efficacy of various antibacterials against both gram-positive and gram-negative bacilli [9, 25-31].”
InfluentialSelf-citationBlaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
CRAIG, W. A., & ANDES, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 435 · cited 3×
“pneumoniae and Haemophilus influenzae in patients with otitis media [38, 43].”
InfluentialSelf-citationDrusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426 · cited 2×
“there is a significant risk of the emergence of resistant subpopulations [29].”
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
Self-citationKinetics of antimicrobial activity
Vogelman, B., & Craig, W. A. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80754-5 · Cited by 315 · cited 4×
“PAE refers to the persistent suppression of bacterial growth following exposure to an antimicrobial [2, 7, 10].”
InfluentialSelf-citation
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
“With the use of in vitro and in vivo evaluations, antibiotics are categorized on the basis of whether they possess concentration-dependent or timedependent effects on microorganisms and on the basis of 4 common PK/PD parameters that predict antibiotic efficacy: the ratio of the maximum serum concentration to the MIC,…”
MethodRybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Self-citationLebeaux, D., Ghigo, J.-M., & Beloin, C. (2014) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00013-14 · Cited by 1,318
Clinical Practice Guideline (Update): Adult Sinusitis
Rosenfeld, R. M., Piccirillo, J. F., Chandrasekhar, S. S., Brook, I., Ashok Kumar, K., Kramper, M., Orlandi, R. R., Palmer, J. N., Patel, Z. M., Peters, A., et al. (2015) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599815572097 · Cited by 1,159
Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu027 · Cited by 1,090
“From a pharmacokinetic/pharmacodynamic (PK/PD) perspective, preclinical studies have defined these antibiotics to be time dependent, that is, the time for which the free (unbound) antibiotic concentration is maintained above the minimum inhibitory concentration (MIC) is the determinate factor associated with bacterial…”
BackgroundAntimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Roberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
Anthrax as a Biological Weapon, 2002: Updated Recommendations for Management
Inglesby, T. V., O'Toole, T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Friedlander, A. M., Gerberding, J., Hauer, J., Hughes, J., et al. (2002) · JAMA · doi:10.1001/jama.287.17.2236 · Cited by 1,027
Horcajada, J. P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N., & Grau, S. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-19 · Cited by 961
“Old in vitro and in vivo PK/PD studies initially defined an fT MIC of 40% as the optimal value for the bactericidal activity of carbapenems (235).”
BackgroundAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
“Again, Craig and colleagues have demonstrated this convincingl”
BackgroundClinical practice guideline: Adult sinusitis
Rosenfeld, R. M., Andes, D., Neil, B., Cheung, D., Eisenberg, S., Ganiats, T. G., Gelzer, A., Hamilos, D., Haydon, R. C., Hudgins, P. A., et al. (2007) · Otolaryngology–Head and Neck Surgery · doi:10.1016/j.otohns.2007.06.726 · Cited by 907
Diagnosis and Management of Acute Otitis Media
Media, S. O. M. O. A. O. (2004) · Pediatrics · doi:10.1542/peds.113.5.1451 · Cited by 902
“If we use bacteriologic cure as a surrogate for clinical efficacy, there is strong evidence that drugs that achieve antibacterial concentrations that are able to eradicate pathogens from the middle-ear fluid are the preferred selection.(80,81) Numerous studies have shown that the common pathogens in AOM are Streptococ…”
Pharmacokinetic issues for antibiotics in the critically ill patient
Roberts, J. A., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181961bff · Cited by 862
“In vivo animal experiments have demonstrated that -lactams have a slow continuous kill characteristic that is almost entirely related to T MIC (71).”
BackgroundMoise-Broder, P. A., Forrest, A., Birmingham, M. C., & Schentag, J. J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00005 · Cited by 757
“[8] Thus far, although vancomycin failure is being Vancomycin is the antibacterial of choice for noted around the world, there has not yet been a difficult-to-treat Staphylococcus aureus infections thorough study of time above MIC or AUC24/MIC that show resistance to β-lactams.”
BackgroundThe future challenges facing the development of new antimicrobial drugs
Coates, A., Hu, Y., Bax, R., & Page, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd940 · Cited by 704
“Measures of drug exposure, such as peak concentration and the area under the concentration versus time curve, relative to a measure of the potency of the drug for the organisms being treated — for example, the minimum inhibitory concentration (MIC) — are linked to clinical outcomes in both animals and human”
BackgroundAmbrose, P. G., Bhavnani, S. M., Rubino, C. M., Louie, A., Gumbo, T., Forrest, A., & Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/510079 · Cited by 697
Heffelfinger, J. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.10.1399 · Cited by 610
Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
(2000) · American Journal of Public Health · doi:10.2105/ajph.90.2.223 · Cited by 589
Setting and Revising Antibacterial Susceptibility Breakpoints
Turnidge, J., & Paterson, D. L. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00047-06 · Cited by 578
Craig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556
Self-citationGuilhaumou, R., Benaboud, S., Bennis, Y., Dahyot-Fizelier, C., Dailly, E., Gandia, P., Goutelle, S., Lefeuvre, S., Mongardon, N., Roger, C., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2378-9 · Cited by 543
Antimicrobial Treatment Guidelines for Acute Bacterial Rhinosinusitis
Partnership, S. A. A. H. (2004) · Otolaryngology–Head and Neck Surgery · doi:10.1016/j.otohns.2003.12.003 · Cited by 535
“97, 107, 108 The goal of dosing regimen is to maximize drug concentration at the site of infection.”
InfluentialJorgensen, J. H., Hindler, J. F., Reller, L. B., & Weinstein, M. P. (2007) · Clinical Infectious Diseases · doi:10.1086/510431 · Cited by 534
Bacterial meningitis in children
Sáez-Llorens, X., & McCracken, G. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13693-8 · Cited by 533
“Their effectiveness is determined by the ratio between the peak concentration or area under the concentration curve of the antibiotic and the MBC of the pathogen [52].”
BackgroundLodise, T. P., Lomaestro, B., & Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/510590 · Cited by 527
“First, it produces a lower peak concentration of the drug; because the bacterial kill rate for these agents is not concentration dependent, this does not present a major disadvantage [15–19].”
BackgroundInfluentialPharmacokinetic/Pharmacodynamic Profile of Voriconazole
Theuretzbacher, U., Ihle, F., & Derendorf, H. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645070-00002 · Cited by 475
The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.
Ulldemolins, M., Roberts, J. A., Rello, J., Paterson, D. L., & Lipman, J. (2011) · Clinical Pharmacokinetics · doi:10.2165/11539220-000000000-00000 · Cited by 469
“Penicillins, cephalosporins and monobactams belong to the b-lactam family of antibacterials and are categorized as ‘timedependent’ antibacterials, where antibacterial activity is related to the ƒT>MIC.([50]) Penicillins and monobactams are reported to require at least 50–60% ƒT>MIC for maximal bactericidal activity, w…”
BackgroundInfluentialMcKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464
Antimicrobial Resistance in Haemophilus influenzae
Tristram, S., Jacobs, M. R., & Appelbaum, P. C. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-06 · Cited by 464
“PK describes the body’s absorption, distribution, metabolism, and elimination of drugs, while PD examines the in vivo relationship between the target pathogen and the antimicrobial agent over time, taking into account the effects of variations in drug concentrations on killing and organism growth dynamics (3, 5, 29).”
BackgroundMatzke, G. R., Aronoff, G. R., Atkinson, A. J., Bennett, W. M., Decker, B. S., Eckardt, K.-U., Golper, T., Grabe, D. W., Kasiske, B., Keller, F., et al. (2011) · Kidney International · doi:10.1038/ki.2011.322 · Cited by 462
Lomovskaya, O., & Bostian, K. A. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.008 · Cited by 460
Pharmacology of the fluoroquinolones: A perspective for the use in domestic animals
Martinez, M. N., McDermott, P. F., & Walker, R. D. (2005) · The Veterinary Journal · doi:10.1016/j.tvjl.2005.07.010 · Cited by 455
Yu, V. L., Chiou, C. C. C., Feldman, C., Ortqvist, A., Rello, J., Morris, A. J., Baddour, L. M., Luna, C. M., Snydman, D. R., Ip, M., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/377534 · Cited by 451
“organisms [33].”
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
Li, Y., Theuretzbacher, U., Clancy, C. J., Nguyen, M. H., & Derendorf, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319340-000000000-00000 · Cited by 450
“Pharmacokinetic/ pharmacodynamic parameters are potentially powerful guides for establishing optimal dosing regimens for existing drugs against emerging pathogens and resistant organisms, for setting susceptibility breakpoints and for choosing appropriate dosing regimens early in drug development.([8]) Although our un…”
BackgroundAntifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444
“This area has been well developed for antibacterial agents, and excellent reviews are available (36, 37, 131).”
BackgroundBlot, S. I., Pea, F., & Lipman, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.07.006 · Cited by 444
“Examples are fluoroquinolones, tigecycline, linezolid and glycopeptides [35].”
BackgroundNation, R. L., & Li, J. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328332e672 · Cited by 443
Subtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients
Udy, A. A., Varghese, J. M., Altukroni, M., Briscoe, S., McWhinney, B. C., Ungerer, J. P., Lipman, J., & Roberts, J. A. (2012) · Chest · doi:10.1378/chest.11-1671 · Cited by 414
Animal model pharmacokinetics and pharmacodynamics: a critical review
Andes, D., & Craig, W. A. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(02)00022-5 · Cited by 413
Self-citationAmphotericin B: time for a new “gold standard”
Saravolatz, L. D., Ostrosky-Zeichner, L., Marr, K. A., Rex, J. H., & Cohen, S. H. (2003) · Clinical Infectious Diseases · doi:10.1086/376634 · Cited by 406
“Pharmacokinetics and pharmacodynamics are another avenue toward understanding of relative drug activities [17], but the pharmacokinetics of AmBD and LFABs are incompletely understood [6, 18, 19], and the available data do not provide strong insights.”
BackgroundVeterinary Drug Usage and Antimicrobial Resistance in Bacteria of Animal Origin
Aarestrup, F. M. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960401.x · Cited by 405
The pharmacokinetic–pharmacodynamic approach to a rational dosage regimen for antibiotics
Toutain, P. L., del Castillo, J. R. E., & Bousquet-Mélou, A. (2002) · Research in Veterinary Science · doi:10.1016/s0034-5288(02)00039-5 · Cited by 384
Cavassin, F. B., Baú-Carneiro, J. L., Vilas-Boas, R. R., & Queiroz-Telles, F. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00382-7 · Cited by 382
“As a result, optimal drug regimens are achieved, and toxicity and resistance development are minimized [114, 115].”
BackgroundRoberts, J. A., Abdul-Aziz, M.-H., Davis, J. S., Dulhunty, J. M., Cotta, M. O., Myburgh, J., Bellomo, R., & Lipman, J. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0024oc · Cited by 379
Augmented Renal Clearance: Implications for Antibacterial Dosing in the Critically Ill
Udy, A. A., Roberts, J. A., Boots, R. J., Paterson, D. L., & Lipman, J. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318140-000000000-00000 · Cited by 377
BTS Guidelines for the Management of Community Acquired Pneumonia in Adults
British Thoracic Society Standards of Care Committee in collaboration with and endorsed by the Royal College of Physicians of London, R. C. O. G. P. (2001) · Thorax · doi:10.1136/thx.56.suppl_4.iv1 · Cited by 377
Quinolones: Action and Resistance Updated
Drlica, K., Hiasa, H., Kerns, R., Malik, M., Mustaev, A., & Zhao, X. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789630947 · Cited by 376
“This pharmacodynamic index (AUC24/MIC) correlates empirically with favorable patient and microbiological outcome [129, 130].”
BackgroundIn Vivo Pharmacodynamic Activity of Daptomycin
Safdar, N., Andes, D., & Craig, W. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.63-68.2004 · Cited by 370
“It is appropriate to compare AUCs in humans with those in mice on the basis of total drug concentrations, as the extent of protein binding is identical in both species (10).”
BackgroundSelf-citationHas antifungal susceptibility testing come of age
Rex, J. H., & Pfaller, M. A. (2002) · Clinical Infectious Diseases · doi:10.1086/342384 · Cited by 361
“dynamic analyses to the best interpretation of MIC values [6, 7].”
BackgroundPrevention of Resistance: A Goal for Dose Selection for Antimicrobial Agents
Drusano, G. L. (2003) · Clinical Infectious Diseases · doi:10.1086/344653 · Cited by 356
“For fluoroquinolones, that exposure target for suppression of resistance is the AUC/MIC ratio, whereas for carbapenems, it is time > MIC [9].”
BackgroundEmergence and spread of antibiotic resistance following exposure to antibiotics
Cantón, R., & Morosini, M.-I. (2011) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00295.x · Cited by 351
Tissue concentrations: do we ever learn?
Mouton, J. W., Theuretzbacher, U., Craig, W. A., Tulkens, P. M., Derendorf, H., & Cars, O. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm476 · Cited by 348
“These relationships show a marked consistency, and the pharmacodynamic index values (such as AUC/MIC) that result in a certain effect have been determined for most classes of antibiotics.(16,17) The pharmacokinetic/pharmacodynamic index values are derived from concentrations measured in serum over time and it is inapp…”
Self-citationA Critical Review of the Fluoroquinolones: Focus on Respiratory Infections
Zhanel, G. G., Ennis, K., Vercaigne, L., Walkty, A., Gin, A. S., Embil, J., Smith, H., & Hoban, D. J. (2002) · Drugs · doi:10.2165/00003495-200262010-00002 · Cited by 344
Application of fluoroquinolone pharmacodynamics
Wright, D. H. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.5.669 · Cited by 342
Clostridium difficile–Associated Diarrhea: A Review
Mylonakis, E., Ryan, E. T., & Calderwood, S. B. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.4.525 · Cited by 339
Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis
Jayaram, R., Gaonkar, S., Kaur, P., Suresh, B. L., Mahesh, B. N., Jayashree, R., Nandi, V., Bharat, S., Shandil, R. K., Kantharaj, E., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2118-2124.2003 · Cited by 335
“On the basis of their in vitro antimicrobial properties, antibacterial agents can be said to show either concentrationdependent killing or time-dependent killing (9, 10).”
BackgroundTherapeutic drug monitoring of β-lactams in critically ill patients: proof of concept
Roberts, J. A., Ulldemolins, M., Roberts, M. S., McWhinney, B., Ungerer, J., Paterson, D. L., & Lipman, J. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.008 · Cited by 334
Hawkey, P. M., Warren, R. E., Livermore, D. M., McNulty, C. A. M., Enoch, D. A., Otter, J. A., & Wilson, A. P. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky027 · Cited by 334
Principles of antibacterial dosing in continuous renal replacement therapy
Choi, G., Gomersall, C. D., Tian, Q., Joynt, G. M., Freebairn, R., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181aab3d0 · Cited by 334
“Route of dilution NS NA NS Mean SD 23 7 ml/kg/hr NA 0.21 0.09 NA 4 g 8 hourly Mean SD 3.42 0.54 L/hr NA NA 0.90 0.33 500–750 mg 12 hourly 1–2 L/hr NA NA NA Initial 1.5 g, then 750 mg 20–24 hourly Mean SD 0.85 0.11 L/hr Not critically ill NA NA 0.86 0.08 500 mg 12 hourly 1–2 L/hr NA 0.69 0.18 NA 2 g 8 hourly (MIC 4 mg/…”
BackgroundInfluentialPharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
Nielsen, E. I., & Friberg, L. E. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005769 · Cited by 332
“It has been recognized however that the maximum is reached at concentrations around four to five times MIC (Craig, 1998).”
BackgroundPharmacodynamic Functions: a Multiparameter Approach to the Design of Antibiotic Treatment Regimens
Regoes, R. R., Wiuff, C., Zappala, R. M., Garner, K. N., Baquero, F., & Levin, B. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3670-3676.2004 · Cited by 332
“And, as is well known for some antibiotics and bacteria, the rate at which the bacteria are killed declines with time (12, 14, 16, 19, 22, 23, 26, 38).”
BackgroundMIC-based dose adjustment: facts and fables
Mouton, J. W., Muller, A. E., Canton, R., Giske, C. G., Kahlmeter, G., & Turnidge, J. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx427 · Cited by 328
Pea, F., Viale, P., & Furlanut, M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00002 · Cited by 327
Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters
Jacobs, M. R. (2001) · Clinical Microbiology and Infection · doi:10.1046/j.1198-743x.2001.00295.x · Cited by 326
Craig, W. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321854 · Cited by 318
“Because higher doses will result in better killing, once-daily dosing of these agents that maximize the peak/MIC ratio could enhance their antimicrobial activity [1, 2].”
BackgroundSelf-citationFluoroquinolones: Action and Resistance
Drlica, K., & Malik, M. (2003) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026033452537 · Cited by 317
“For fluoroquinolones, the empirical pharmacodynamic indices AUC/MIC and Cmax/MIC are related to favorable patient outcome with some infections [196, 197].”
BackgroundJacobs, M. R., Bajaksouzian, S., Zilles, A., Lin, G., Pankuch, G. A., & Appelbaum, P. C. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.8.1901 · Cited by 317
“Different PK/PD parameters correlate with clinical outcome with fluoroquinolones and with azalides such as azithromycin, and breakpoints can be derived from one of two ratios—the ratio of the peak concentration in serum to the MIC or the ratio of the area under the 24-h serum concentration-time curve (AUC) to the MIC…”
BackgroundMethodInfluentialReview of Eravacycline, a Novel Fluorocycline Antibacterial Agent
Zhanel, G. G., Cheung, D., Adam, H., Zelenitsky, S., Golden, A., Schweizer, F., Gorityala, B., Lagacé-Wiens, P. R. S., Walkty, A., Gin, A. S., et al. (2016) · Drugs · doi:10.1007/s40265-016-0545-8 · Cited by 317
Therapeutic drug monitoring of antimicrobials
Roberts, J. A., Norris, R., Paterson, D. L., & Martin, J. H. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04080.x · Cited by 316
Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., O'Brien, R. J., Vernon, A. N., Chaisson, R. E., Bishai, W. R., & Grosset, J. H. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200310-1380oc · Cited by 314
“Because the magnitude of the AUC-to-MIC ratio correlates with the bactericidal activity of the fluoroquinolones against other bacterial pathogens ( 32 ), the 100-mg/kg dose is more likely to underestimate rather than overestimate the activity to be expected in humans.”
BackgroundAbdul-Aziz, M. H., Sulaiman, H., Mat-Nor, M.-B., Rai, V., Wong, K. K., Hasan, M. S., Abd Rahman, A. N., Jamal, J. A., Wallis, S. C., Lipman, J., et al. (2016) · Intensive Care Medicine · doi:10.1007/s00134-015-4188-0 · Cited by 308
“Beta-lactam antibiotics display time-dependent activity where bacterial killing and treatment efficacy correlate with the duration of time (T) that free (unbound) plasma drug concentrations remain above the minimum inhibitory concentration (MIC) of the offending pathogen (fT[MIC) [3].”
BackgroundThe Glycylcyclines: A Comparative Review with the Tetracyclines
Zhanel, G. G., Homenuik, K., Nichol, K., Noreddin, A., Vercaigne, L., Embil, J., Gin, A., Karlowsky, J. A., & Hoban, D. J. (2004) · Drugs · doi:10.2165/00003495-200464010-00005 · Cited by 306
Review of Macrolides and Ketolides: Focus on Respiratory Tract Infections
Zhanel, G. G., Dueck, M., Hoban, D. J., Vercaigne, L. M., Embil, J. M., Gin, A. S., & Karlowsky, J. A. (2001) · Drugs · doi:10.2165/00003495-200161040-00003 · Cited by 304
“Under conditions in which a Cmax : MIC ratio of at least 10 : 1 is achieved, concentration-dependent agents achieve excellent levels of bacterial death, clinical cure and prevent thedevelopmentofbacterial resistance.[181-186] Bacterial death, clinical cure and prevention of resistance development for concentration-dep…”
BackgroundIssues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves versus MIC
Mueller, M., de la Peña, A., & Derendorf, H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.2.369-377.2004 · Cited by 304
Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine
MCKELLAR, Q. A., SANCHEZ BRUNI, S. F., & JONES, D. G. (2004) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2004.00603.x · Cited by 302
“Alternatively it may be dependent on maintaining concentrations in plasma just above the MIC for a prolonged time (Craig, 1998a) and, for some drugs and pathogens, a combination of concentration and time of exposure may be important (co-dependency).”
BackgroundInfluentialAmbrose, P. G., Grasela, D. M., Grasela, T. H., Passarell, J., Mayer, H. B., & Pierce, P. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2793-2797.2001 · Cited by 299
“The clearance estimates were then used in conjunction with dose to obtain a total-drug AUC24 for each patient (equation 3). total-drug AUC24 dose/clearance ( 3 )”
BackgroundMethodBall, P. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.1.31 · Cited by 290
“Standard in vitro MICs give no information on the time-course of antibacterial activity, but integration of MIC with pharmacokinetic (PK) parameters provides PK/PD indices, which are valuable tools with which to predict antibacterial effects and optimal drug dosage.(48,49) Such indices include: the time for which non-…”
BackgroundPharmacokinetics and Pharmacodynamics of Fluoroquinolones
Turnidge, J. (1999) · Drugs · doi:10.2165/00003495-199958002-00006 · Cited by 289
Mouton, J. W., Brown, D. F. J., Apfalter, P., Cantón, R., Giske, C. G., Ivanova, M., MacGowan, A. P., Rodloff, A., Soussy, C.-J., Steinbakk, M., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03752.x · Cited by 286
“The PDT is therefore most often derived from preclinical studies, such as studies in animal models [18,19], but in vitro hollow fibre infection models [20–22] are increasingly used.”
LaPlante, K. L., & Rybak, M. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4665-4672.2004 · Cited by 284
“The therapeutic efficacy of vancomycin has been pharmacodynamically correlated with both T MIC and AUC over 24 h divided by the MIC (AUC/MIC) (20, 38).”
BackgroundRoberts, J. A., & Lipman, J. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645080-00001 · Cited by 283
“[153] ed[46,163] and pharmacoeconomic advantages from a reduced total daily dose may still be conferred.”
BackgroundCurrent drug therapy and pharmaceutical challenges for Chagas disease
Bermúdez, J. M. A., Davies, C., Simonazzi, A., Real, J. P., & Palma, S. D. (2015) · Acta Tropica · doi:10.1016/j.actatropica.2015.12.017 · Cited by 283
In Vivo Pharmacodynamics of a New Oxazolidinone (Linezolid)
Andes, D., van Ogtrop, M. L., Peng, J., & Craig, W. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3484-3489.2002 · Cited by 278
Self-citationBTS Guidelines for the Management of Community Acquired Pneumonia in Adults.
(2001) · PubMed · doi:10.1136/thorax.56.suppl_4.iv1 · Cited by 272
Metlay, J. P., Hofmann, J., Cetron, M. S., Fine, M. J., Farley, M. M., Whitney, C., & Breiman, R. F. (2000) · Clinical Infectious Diseases · doi:10.1086/313716 · Cited by 270
“Recent work has highlighted the degree to which in vitro susceptibility results do not directly correlate with the predicted in vivo efficacy of antimicrobial drugs [10].”
BackgroundIssues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Distribution in Tissue
Müller, M., dela Peña, A., & Derendorf, H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1441-1453.2004 · Cited by 268
“Therefore, several authors proposed that PK be linked to PD in a more dynamic way by using several PK-PD models (35, 39, 42, 44, 119).”
MethodA Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis
Dulhunty, J. M., Roberts, J. A., Davis, J. S., Webb, S. A. R., Bellomo, R., Gomersall, C., Shirwadkar, C., Eastwood, G. M., Myburgh, J., Paterson, D. L., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-0857oc · Cited by 264
Resistance among Streptococcus pneumoniae:Implications for Drug Selection
Appelbaum, P. C. (2002) · Clinical Infectious Diseases · doi:10.1086/340400 · Cited by 260
“pneumoniae infection in animal models has shown that the survival rate was nearly 0% when serum levels exceeded the MIC for 20% of the dosing interval but was 90%–100% when serum concentrations were higher than the MIC value for 40%–50% of the dosing interval [63].”
BackgroundInfluentialPai, M. P., & Bearden, D. T. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.8.1081 · Cited by 256
“Recognition of the naïvety of this approach has led to the science of pharmacodynamics, which interrelates pharmacokinetic parameters against the MICs of the pathogens being treated.(12) The three most common antimicrobial pharmacodynamic parameters are the peak concentration (Cmax):MIC ratio, the area under the conce…”
BackgroundInfluentialNielsen, E. I., Cars, O., & Friberg, L. E. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00182-11 · Cited by 254
“The magnitude of fT MICs required for bactericidal effect was in this study estimated to be about 40%, which is also in agreement to previously reported values of 35 to 50% (12, 13, 15, 33).”
BackgroundResultInfluentialToutain, P., & Lees, P. (2004) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2004.00613.x · Cited by 252
“In several infection models with a range of gram-positive and gram-negative bacteria, for fluoroquinolones AUC/MIC ratios of 30 h were associated with more than 50% mortality, whereas with AUC/MIC ratios of ‡100 h there was almost no mortality (Craig, 1998).”
BackgroundInfluentialVancomycin: We Can't Get There From Here
Patel, N., Pai, M. P., Rodvold, K. A., Lomaestro, B., Drusano, G. L., & Lodise, T. P. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir078 · Cited by 247
Rodvold, K. A., George, J. M., & Yoo, L. (2011) · Clinical Pharmacokinetics · doi:10.2165/11594090-000000000-00000 · Cited by 246
“The concepts and categorization of the pharmacokineticpharmacodynamic parameters of anti-infective agents have been based on relationships established from plasma or serum concentrations.([2-4]) We are unaware of any clinical studies that have evaluated and documented similar correlations with concentrations at the si…”
InfluentialManagement of meningitis due to antibiotic-resistant Acinetobacter species
Kim, B.-N., Peleg, A. Y., Lodise, T. P., Lipman, J., Li, J., Nation, R., & Paterson, D. L. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70055-6 · Cited by 244
Lodise, T. P., Lomaestro, B. M., & Drusano, G. L. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.9.1320 · Cited by 243
Drusano, G. L., Preston, S. L., Hardalo, C., Hare, R., Banfield, C., Andes, D., Vesga, O., & Craig, W. A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.13-22.2001 · Cited by 243
“One can also see this in the data published by Craig (2) for multiple animal models, in which the near-Emax value of the AUC/MIC ratio is approximately 100/1.”
BackgroundSelf-citationAntibiotic Pharmacodynamics in Cerebrospinal Fluid
Lutsar, I., McCracken, Jr., & Friedland, I. R. (1998) · Clinical Infectious Diseases · doi:10.1086/515003 · Cited by 242
“Almost all antibiotics demonstrate a prolonged PAE with gram-positive bacteria in vitro [1].”
BackgroundInfluentialTuntland, T., Ethell, B., Kosaka, T., Blasco, F., Zang, R. X., Jain, M., Gould, T., & Hoffmaster, K. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00174 · Cited by 239
“Antimicrobial agents can be categorized on the basis of the PK/PD measure that is most predictive of efficacy (Craig, 1998; Andes and Craig, 2002).”
BackgroundMethodInfluentialJumbe, N., Louie, A., Leary, R., Liu, W., Deziel, M. R., Tam, V. H., Bachhawat, R., Freeman, C., Kahn, J. B., Bush, K., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16814 · Cited by 238
“The mouse-thigh infection model pio-neered by Eagle and colleagues (1) and greatly expanded upon by Craig (2, 3) was used as our experimental disease system.”
Second messenger signalling governs Escherichia coli biofilm induction upon ribosomal stress
Boehm, A., Steiner, S., Zaehringer, F., Casanova, A., Hamburger, F., Ritz, D., Keck, W., Ackermann, M., Schirmer, T., & Jenal, U. (2009) · Molecular Microbiology · doi:10.1111/j.1365-2958.2009.06739.x · Cited by 233
“In patients undergoing antimicrobial chemotherapy, pathogens can be exposed to subinhibitory concentrations of drugs for several hours (Craig, 1998).”
Background
Metadata
- Authors
- Craig, W. A.
- Affiliations
- William S. Middleton Memorial Veterans Hospital (US)
- Corresponding author
- Craig, William A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-01
- Volume
- 26
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2113717321
- Cited by
- 2,908
- References
- 50
- Citations by year
- 2026: 68 · 2025: 81 · 2024: 82 · 2023: 99 · 2022: 86 · 2021: 89 · 2020: 103 · 2019: 94 · 2018: 105 · 2017: 124 · 2016: 136 · 2015: 113 · 2014: 129 · 2013: 109 · 2012: 101
- FWCI
- 54.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- pharmacokinetics/pharmacodynamics, dosing regimen, pharmacodynamic parameters, pharmacokinetic parameters, animal models of infection, human infection, susceptibility breakpoints, antimicrobial resistance, emerging pathogens, drug development costs
- MeSH terms
- Animals, Anti-Bacterial Agents, Bacteria, Humans, Lactams, Microbial Sensitivity Tests, Fluoroquinolones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.